How many patents does
Novo Nordisk have?
patents
6,948
families
1,047
granted
1,675
applications
5,273
US
1,614
EP
1,195
CN
861
WO
679
JP
553
KR
106
GB
1
RoW
1,939
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Novo Nordisk
Top ten assignees appearing on patents
2009 - 2018
| novo nordisk | 5138 |
| novo nordisk health care | 284 |
| novozymes | 150 |
| innate pharma | 105 |
| biogenerix | 88 |
| high point pharmaceuticals | 63 |
| neose technologies | 55 |
| g2 inflammation | 46 |
| ratiopharm | 44 |
| roche | 24 |
2009
| novo nordisk | 607 |
| novozymes | 32 |
| neose technologies | 24 |
| novo nordisk health care | 23 |
| g2 inflammation | 11 |
| biogenerix | 9 |
| high point pharmaceuticals | 8 |
| innate pharma | 5 |
| dr. reddy's laboratories | 4 |
| arkema | 4 |
2018
| novo nordisk | 449 |
| novo nordisk health care | 12 |
| amgen | 10 |
| roche | 8 |
| innate pharma | 5 |
| carbogen amcis | 1 |
| argos therapeutics | 1 |
| axelsen, mads | 1 |
| ratiopharm | 1 |
| takara bio europe | 1 |
Novo Nordisk
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| remodeling and glycoconjugation of peptides | 95 | 2001 |
| double-acylated glp-1 derivatives | 46 | 2009 |
| protease stabilized, acylated insulin analogues | 46 | 2008 |
| conjugated factor viii molecules | 44 | 2008 |
| methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies | 44 | 2003 |
| novel insulin derivatives | 44 | 2003 |
| preparation comprising insulin, nicotinamide and an amino acid | 41 | 2009 |
| device for injecting apportioned doses of liquid drug | 39 | 2008 |
| stable growth hormone compounds | 39 | 2010 |
| analogs of glucagon exhibiting gip receptor activity | 37 | 2012 |